Ad
related to: ewing sarcoma solid tumor marker
Search results
Results From The WOW.Com Content Network
Ewing sarcoma occurs about 10- to 20-fold more commonly in people of European descent compared to people of African descent. [49] [10] Ewing sarcoma is the second most common bone cancer in children and adolescents, with poor prognosis and outcome in ~70% of initial diagnoses and 10–15% of relapses. [50]
Small blue round cells of Ewing Sarcoma Display of small round blue cells characteristic of desmoplastic small round cell tumour.. In histopathology, a small-blue-round-cell tumour (abbreviated SBRCT), also known as a small-round-blue-cell tumor (SRBCT) or a small-round-cell tumour (SRCT), is any one of a group of malignant neoplasms that have a characteristic appearance under the microscope ...
PNETs and Ewing’s sarcoma are described as appearing on the same histologic spectrum. [8] [9] Treatment of PNETs is the same as extra-osseous Ewing’s sarcoma, with resection of the whole tumor alongside chemotherapy and radiation. Outcomes however are poor as PNET remains an aggressive cancer as a member of the Ewing Family of Tumors. [9]
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers ... Ewing sarcoma, primitive neuroectodermal tumor, ...
Antibodies to CD99 are used in diagnostic immunohistochemistry to distinguish Ewing's sarcoma from other tumours of similar histological appearance, as well as for the identification of thymic tumours, and of spindle cell tumours, such as synovial sarcoma, haemangiopericytoma, and meningioma. [6]
EWS/FLI1 is an oncogenic protein that is pathognomonic for Ewing sarcoma. [1] It is found in approximately 90% of all Ewing sarcoma tumors with the remaining 10% of fusions substituting one fusion partner with a closely related family member (e.g. ERG for FLI1). [2]
The peripheral PNET (pPNET) is now thought to be virtually identical to Ewing sarcoma: "Current evidence indicates that both Ewing's sarcoma and PNET have a similar neural phenotype and, because they share an identical chromosome translocation, they should be viewed as the same tumor, differing only in their degree of neural differentiation.
In this model, enforced expression of DNAM-1 ligands CD155 and CD112 increased tumor rejection. CD155 and CD112 are expressed on the surface of a wide number of tumor cells in solid and lymphoid malignances such as lung carcinoma, primary human leukemia, myeloma, melanoma, neuroblastoma, ovarian cancer, colorectal carcinoma, and Ewing sarcoma ...